RAPP (STOCKS)
Rapport Therapeutics, Inc. Common Stock
$47.420000
+0.060000 (+0.13%)
Prev close: $47.360000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Abraham N. Ceesay, MBA
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,278.83M
- Employees
- 69
- P/E (TTM)
- -15.59
- P/B (TTM)
- 5.38
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-1.19 | $-0.97 | -0.2167 | -22.26% |
|
Mar 2026 (Q1)
|
$-0.42 | $-0.68 | +0.2642 | +38.61% |
|
Dec 2025 (Q4)
|
$-0.72 | $-0.69 | -0.0284 | -4.11% |
|
Sep 2025 (Q3)
|
$-0.71 | $-0.79 | +0.0809 | +10.23% |
Financial Statements
| Revenues | $20.00M |
| Nonoperating Income/Loss | $16.36M |
| Operating Expenses | $173.52M |
| Research and Development | $136.67M |
| Operating Income/Loss | -$153.52M |
| Income/Loss From Continuing Operations After Tax | -$137.16M |
| Income/Loss From Continuing Operations Before Tax | -$137.16M |
| Net Income/Loss | -$137.16M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$137.16M |
| Net Income/Loss Available To Common Stockholders, Basic | -$137.16M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.03 |
| Diluted Earnings Per Share | -$3.03 |
| Basic Average Shares | 135,351,644 |
| Diluted Average Shares | 135,351,644 |
| Assets | $458.98M |
| Current Assets | $446.86M |
| Noncurrent Assets | $12.13M |
| Fixed Assets | $2.34M |
| Other Non-current Assets | $9.79M |
| Liabilities | $36.06M |
| Current Liabilities | $28.42M |
| Accounts Payable | $2.80M |
| Wages | $4.25M |
| Other Current Liabilities | $21.38M |
| Noncurrent Liabilities | $7.63M |
| Equity | $422.93M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $422.93M |
| Liabilities And Equity | $458.98M |
| Net Cash Flow From Operating Activities | -$96.68M |
| Net Cash Flow From Operating Activities, Continuing | -$96.68M |
| Net Cash Flow From Investing Activities | -$167.56M |
| Net Cash Flow From Investing Activities, Continuing | -$167.56M |
| Net Cash Flow From Financing Activities | $272.79M |
| Net Cash Flow From Financing Activities, Continuing | $272.79M |
| Net Cash Flow | $8.55M |
| Net Cash Flow, Continuing | $8.55M |
| Comprehensive Income/Loss | -$138.35M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$138.35M |
| Other Comprehensive Income/Loss | -$28.12M |
| Other Comprehensive Income/Loss Attributable To Parent | -$1.19M |